查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1750810

医药契约製造和实验室服务市场规模、份额、趋势分析报告：按服务、地区和细分市场预测，2025 年至 2030 年

Pharmaceutical Contract Manufacturing And Research Services Market Size, Share & Trends Analysis Report By Service (Manufacturing, Research), By Region (North America, Europe, Asia Pacific, Latin America), And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

製药契约製造和研究服务市场的成长和趋势：

根据Grand View Research, Inc.的最新报告，全球医药契约製造和实验室服务市场规模预计到2030年将达到3,952.3亿美元，2025年至2030年期间的复合年增长率为6.9%。

製药公司越来越多地转向CMO和CDMO，以避免在基础设施方面进行大规模资本投资，并应对复杂的监管环境。这项策略措施使他们能够将资源集中在核心竞争力上，例如药物研发和商业化。专业合约组织实现的规模经济也有助于降低生产成本。

药物开发日益复杂，尤其生技药品、生物相似药、高效能原料药和个人化药物而言，这需要合约服务提供者俱备先进的能力和专业知识。这些机构通常持有最尖端科技，例如连续生产和先进的处理系统，这些技术对于高效合规的生产至关重要。

全球健康趋势，例如慢性病盛行率上升，以及由于专利到期而对价格合理的学名药和生物类似药的需求，也是主要的成长动力。日益严格且不断变化的法规环境，加上快速进入市场的需求，促使製药公司利用CMO和CDMO的成熟专业知识。向亚太地区等成本竞争力强的地区进行策略性地理转移，以及提供全面解决方案的CRO-CDMO一体化模式的出现，支撑了该市场的蓬勃发展。

医药契约製造和研究服务市场报告重点

  • 生产学名药、生物相似药和疫苗的规模和成本效益的需求正在推动市场的发展。
  • 契约製造提供必要的产能、灵活性和监管支持，以推动亚太地区的发展。
  • 预计在预测期内，医药契约製造的复合年增长率最快，为 7.0%。
  • 复杂领域的研发不断增加以及对 CRO 专业知识的需求使得透过先进技术和遵循复杂法规可以节省全球临床临床实验的成本和时间。
  • 亚太地区医药契约製造和实验室服务市场占据全球市场主导地位，2024 年的收入份额超过 40.0%。这是由于製造能力的扩大和对 CMO 的投资增加，以及新加坡、中国和印度等新兴经济体外包业务的增加。
  • 2024年11月，瑞士龙沙公司宣布大幅扩建其位于菲斯普的生物偶联产能。该投资将包括新增两套1,200公升的生产设施，以满足不断增长的市场需求。

目录

第一章调查方法与范围

第二章执行摘要

第三章製药契约製造和实验室服务市场变数、趋势和范围

  • 市场展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 医药契约製造与研究服务市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章：医药契约製造和研究服务市场：按服务估算和趋势分析

  • 服务细分细分仪表板
  • 医药契约製造与研究服务市场：服务波动分析
  • 全球医药契约製造和研究服务市场规模和趋势分析（按服务，2018-2030 年）
  • 製造业
    • 原料药/原料药
    • 先进的药物传输配方
    • 包裹
    • 最终剂量配方
  • 研究
    • 肿瘤学
    • 疫苗
    • 发炎和免疫学
    • 心臟病学
    • 神经科学
    • 其他的

第五章：医药契约製造与研究服务市场：区域估计与趋势分析

  • 区域市场仪表板
  • 2024 年及 2030 年区域市场占有率分析
  • 医药契约製造和实验室服务市场（按地区）：关键要点
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第六章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • Key company heat map analysis, 2024
  • 公司简介
    • Catalent, Inc（Novo Holdings A/S）
    • PPD（Thermo Fisher Scientific Inc.）
    • AbbVie Inc.
    • Advent International, LP
    • Grifols
    • Dalton Pharma Services
    • Boehringer Ingelheim International GmbH
    • Lonza
Product Code: GVR-1-68038-924-1

Pharmaceutical Contract Manufacturing And Research Services Market Growth & Trends:

The global pharmaceutical contract manufacturing and research services market size is anticipated to reach USD 395.23 billion by 2030 and is projected to grow at a CAGR of 6.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. Pharmaceutical companies are increasingly leveraging CMOs and CDMOs to avoid substantial capital investments in infrastructure and navigate complex regulatory landscapes. This strategic move allows them to concentrate resources on core competencies like drug discovery and commercialization. The economies of scale achieved by specialized contract organizations further contribute to reduced production costs.

The escalating complexity of drug development, particularly in biologics, biosimilars, HPAPIs, and personalized medicine, necessitates the advanced capabilities and expertise readily available within contract service providers. These organizations often possess cutting-edge technologies such as continuous manufacturing and sophisticated handling systems, which prove vital for efficient and compliant production.

Global health trends, including the rising prevalence of chronic diseases and the demand for affordable generics and biosimilars following patent expirations, are also key growth drivers. The stringent and evolving regulatory environment, coupled with the imperative for faster market entry, incentivizes pharmaceutical companies to utilize the established expertise of CMOs and CDMOs. The strategic geographic shifts towards cost-competitive regions like Asia-Pacific and the emergence of integrated CRO-CDMO models offering comprehensive solutions underscore the dynamic growth of this market.

Pharmaceutical Contract Manufacturing And Research Services Market Report Highlights:

  • Based on service, pharmaceutical contract manufacturing services dominated the market with over 60.0% of the total revenue share in 2024, driven by the need for scale and cost efficiency in producing generics, biosimilars, and vaccines.
  • Contract manufacturers offer essential capacity, flexibility, and regulatory support, facilitating growth in regions like Asia-Pacific.
  • Pharmaceutical contract research services are projected to witness the fastest CAGR of 7.0% over the forecast period.
  • Increasing R&D in complex areas and the demand for CROs' specialized expertise offer cost and time savings in global trials through advanced technologies and navigating regulatory complexities.
  • The Asia Pacific pharmaceutical contract manufacturing and research services market dominated the global market with a revenue share of more than 40.0% in 2024, supported by increased outsourcing in developing economies like Singapore, China, and India, which have expanding manufacturing capabilities and significant CMO investments.
  • In November 2024, Lonza (Switzerland) announced a significant expansion of its bioconjugation capabilities in Visp. This investment includes adding two 1,200L manufacturing suites to meet increasing market demand.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Service
    • 1.2.2. Regional scope
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Service outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Pharmaceutical Contract Manufacturing And Research Services Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Pharmaceutical Contract Manufacturing And Research Services Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Pharmaceutical Contract Manufacturing And Research Services Market: Service Estimates & Trend Analysis

  • 4.1. Service Segment Dashboard
  • 4.2. Pharmaceutical Contract Manufacturing And Research Services Market: Service Movement Analysis
  • 4.3. Global Pharmaceutical Contract Manufacturing And Research Services Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
  • 4.4. Manufacturing
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. API/Bulk Drugs
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Advanced Drug Delivery Formulations
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Packaging
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Finished Dose Formulations
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.5.2. Solid
        • 4.4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.5.3. Liquid
        • 4.4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.5.4. Semi-solid Formulations
        • 4.4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Research
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2. Oncology
      • 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3. Vaccines
      • 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4. Inflammation & Immunology
      • 4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.5. Cardiology
      • 4.5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.6. Neuroscience
      • 4.5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.7. Others
      • 4.5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Pharmaceutical Contract Manufacturing And Research Services Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Market Dashboard
  • 5.2. Regional Market Share Analysis, 2024 & 2030
  • 5.3. Pharmaceutical contract manufacturing and research services market by Region: Key Takeaways
  • 5.4. North America
    • 5.4.1. U.S.
      • 5.4.1.1. Key country dynamics
      • 5.4.1.2. Regulatory framework/ reimbursement structure
      • 5.4.1.3. Competitive scenario
      • 5.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Canada
      • 5.4.2.1. Key country dynamics
      • 5.4.2.2. Regulatory framework/ reimbursement structure
      • 5.4.2.3. Competitive scenario
      • 5.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Mexico
      • 5.4.3.1. Key country dynamics
      • 5.4.3.2. Regulatory framework/ reimbursement structure
      • 5.4.3.3. Competitive scenario
      • 5.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Europe
    • 5.5.1. UK
      • 5.5.1.1. Key country dynamics
      • 5.5.1.2. Regulatory framework/ reimbursement structure
      • 5.5.1.3. Competitive scenario
      • 5.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. Germany
      • 5.5.2.1. Key country dynamics
      • 5.5.2.2. Regulatory framework/ reimbursement structure
      • 5.5.2.3. Competitive scenario
      • 5.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.3. France
      • 5.5.3.1. Key country dynamics
      • 5.5.3.2. Regulatory framework/ reimbursement structure
      • 5.5.3.3. Competitive scenario
      • 5.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.4. Italy
      • 5.5.4.1. Key country dynamics
      • 5.5.4.2. Regulatory framework/ reimbursement structure
      • 5.5.4.3. Competitive scenario
      • 5.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.5. Spain
      • 5.5.5.1. Key country dynamics
      • 5.5.5.2. Regulatory framework/ reimbursement structure
      • 5.5.5.3. Competitive scenario
      • 5.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.6. Denmark
      • 5.5.6.1. Key country dynamics
      • 5.5.6.2. Regulatory framework/ reimbursement structure
      • 5.5.6.3. Competitive scenario
      • 5.5.6.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.7. Sweden
      • 5.5.7.1. Key country dynamics
      • 5.5.7.2. Regulatory framework/ reimbursement structure
      • 5.5.7.3. Competitive scenario
      • 5.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.8. Norway
      • 5.5.8.1. Key country dynamics
      • 5.5.8.2. Regulatory framework/ reimbursement structure
      • 5.5.8.3. Competitive scenario
      • 5.5.8.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Asia Pacific
    • 5.6.1. China
      • 5.6.1.1. Key country dynamics
      • 5.6.1.2. Regulatory framework/ reimbursement structure
      • 5.6.1.3. Competitive scenario
      • 5.6.1.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.2. Japan
      • 5.6.2.1. Key country dynamics
      • 5.6.2.2. Regulatory framework/ reimbursement structure
      • 5.6.2.3. Competitive scenario
      • 5.6.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.3. India
      • 5.6.3.1. Key country dynamics
      • 5.6.3.2. Regulatory framework/ reimbursement structure
      • 5.6.3.3. Competitive scenario
      • 5.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.4. Australia
      • 5.6.4.1. Key country dynamics
      • 5.6.4.2. Regulatory framework/ reimbursement structure
      • 5.6.4.3. Competitive scenario
      • 5.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.5. South Korea
      • 5.6.5.1. Key country dynamics
      • 5.6.5.2. Regulatory framework/ reimbursement structure
      • 5.6.5.3. Competitive scenario
      • 5.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.6. Thailand
      • 5.6.6.1. Key country dynamics
      • 5.6.6.2. Regulatory framework/ reimbursement structure
      • 5.6.6.3. Competitive scenario
      • 5.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Latin America
    • 5.7.1. Brazil
      • 5.7.1.1. Key country dynamics
      • 5.7.1.2. Regulatory framework/ reimbursement structure
      • 5.7.1.3. Competitive scenario
      • 5.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.2. Argentina
      • 5.7.2.1. Key country dynamics
      • 5.7.2.2. Regulatory framework/ reimbursement structure
      • 5.7.2.3. Competitive scenario
      • 5.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. MEA
    • 5.8.1. South Africa
      • 5.8.1.1. Key country dynamics
      • 5.8.1.2. Regulatory framework/ reimbursement structure
      • 5.8.1.3. Competitive scenario
      • 5.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.2. Saudi Arabia
      • 5.8.2.1. Key country dynamics
      • 5.8.2.2. Regulatory framework/ reimbursement structure
      • 5.8.2.3. Competitive scenario
      • 5.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.3. UAE
      • 5.8.3.1. Key country dynamics
      • 5.8.3.2. Regulatory framework/ reimbursement structure
      • 5.8.3.3. Competitive scenario
      • 5.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.4. Kuwait
      • 5.8.4.1. Key country dynamics
      • 5.8.4.2. Regulatory framework/ reimbursement structure
      • 5.8.4.3. Competitive scenario
      • 5.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
  • 6.3. Vendor Landscape
    • 6.3.1. Key company heat map analysis, 2024
  • 6.4. Company Profiles
    • 6.4.1. Catalent, Inc (Novo Holdings A/S)
      • 6.4.1.1. Company overview
      • 6.4.1.2. Financial performance
      • 6.4.1.3. Product benchmarking
      • 6.4.1.4. Strategic initiatives
    • 6.4.2. PPD (Thermo Fisher Scientific Inc.)
      • 6.4.2.1. Company overview
      • 6.4.2.2. Financial performance
      • 6.4.2.3. Product benchmarking
      • 6.4.2.4. Strategic initiatives
    • 6.4.3. AbbVie Inc.
      • 6.4.3.1. Company overview
      • 6.4.3.2. Financial performance
      • 6.4.3.3. Product benchmarking
      • 6.4.3.4. Strategic initiatives
    • 6.4.4. Advent International, L.P.
      • 6.4.4.1. Company overview
      • 6.4.4.2. Financial performance
      • 6.4.4.3. Product benchmarking
      • 6.4.4.4. Strategic initiatives
    • 6.4.5. Grifols
      • 6.4.5.1. Company overview
      • 6.4.5.2. Financial performance
      • 6.4.5.3. Product benchmarking
      • 6.4.5.4. Strategic initiatives
    • 6.4.6. Dalton Pharma Services
      • 6.4.6.1. Company overview
      • 6.4.6.2. Financial performance
      • 6.4.6.3. Product benchmarking
      • 6.4.6.4. Strategic initiatives
    • 6.4.7. Boehringer Ingelheim International GmbH
      • 6.4.7.1. Company overview
      • 6.4.7.2. Financial performance
      • 6.4.7.3. Product benchmarking
      • 6.4.7.4. Strategic initiatives
    • 6.4.8. Lonza
      • 6.4.8.1. Company overview
      • 6.4.8.2. Financial performance
      • 6.4.8.3. Product benchmarking
      • 6.4.8.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global pharmaceutical contract manufacturing and research services market, by region, 2018 - 2030 (USD Million)
  • Table 3 Global pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 4 North America pharmaceutical contract manufacturing and research services market, by country, 2018 - 2030 (USD Million)
  • Table 5 North America pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 6 U.S. pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 7 Canada pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 8 Mexico pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 9 Europe pharmaceutical contract manufacturing and research services market, by country, 2018 - 2030 (USD Million)
  • Table 10 Europe pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 11 UK pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 12 Germany pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 13 France pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 14 Italy pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 15 Spain pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 16 Denmark pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 17 Sweden pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 18 Norway pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 19 Asia Pacific pharmaceutical contract manufacturing and research services market, by country, 2018 - 2030 (USD Million)
  • Table 20 Asia Pacific pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 21 China pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 22 Japan pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 23 India pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 24 Australia pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 25 South Korea pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 26 Thailand pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 27 Latin America pharmaceutical contract manufacturing and research services market, by country, 2018 - 2030 (USD Million)
  • Table 28 Latin America pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 29 Brazil pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 30 Argentina pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 31 MEA pharmaceutical contract manufacturing and research services market, by region, 2018 - 2030 (USD Million)
  • Table 32 MEA pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 33 South Africa pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 34 Saudi Arabia pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 35 UAE pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 36 Kuwait pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Pharmaceutical contract manufacturing and research services market: market outlook
  • Fig. 10 Pharmaceutical contract manufacturing and research services competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 Pharmaceutical contract manufacturing and research services market driver impact
  • Fig. 16 Pharmaceutical contract manufacturing and research services market restraint impact
  • Fig. 17 Pharmaceutical contract manufacturing and research services market strategic initiatives analysis
  • Fig. 18 Pharmaceutical contract manufacturing and research services market: Service movement analysis
  • Fig. 19 Pharmaceutical contract manufacturing and research services market: Service outlook and key takeaways
  • Fig. 20 Manufacturing estimates and forecast, 2018 - 2030
  • Fig. 21 API/bulk drugs estimates and forecast, 2018 - 2030
  • Fig. 22 Advanced drug delivery formulations estimates and forecast, 2018 - 2030
  • Fig. 23 Packaging estimates and forecast, 2018 - 2030
  • Fig. 24 Finished dose formulations estimates and forecast, 2018 - 2030
  • Fig. 25 Solid estimates and forecast, 2018 - 2030
  • Fig. 26 Liquid estimates and forecast, 2018 - 2030
  • Fig. 27 Semi-solid formulations estimates and forecast, 2018 - 2030
  • Fig. 28 Research estimates and forecast, 2018 - 2030
  • Fig. 29 Oncology estimates and forecast, 2018 - 2030
  • Fig. 30 Vaccines estimates and forecast, 2018 - 2030
  • Fig. 31 Inflammation & immunology estimates and forecast, 2018 - 2030
  • Fig. 32 Cardiology estimates and forecast, 2018 - 2030
  • Fig. 33 Neuroscience estimates and forecast, 2018 - 2030
  • Fig. 34 Others estimates and forecast, 2018 - 2030
  • Fig. 35 Global pharmaceutical contract manufacturing and research services market: Regional movement analysis
  • Fig. 36 Global pharmaceutical contract manufacturing and research services market: Regional outlook and key takeaways
  • Fig. 37 North America market estimates and forecasts, 2018 - 2030
  • Fig. 38 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 39 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 40 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 41 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 42 UK market estimates and forecasts, 2018 - 2030
  • Fig. 43 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 44 France market estimates and forecasts, 2018 - 2030
  • Fig. 45 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 46 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 47 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 48 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 49 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 50 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 51 China market estimates and forecasts, 2018 - 2030
  • Fig. 52 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 53 India market estimates and forecasts, 2018 - 2030
  • Fig. 54 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 55 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 56 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 57 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 58 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 59 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 60 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 61 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 62 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 63 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 64 Kuwait market estimates and forecasts, 2018 - 2030